BlackRock Inc. purchased a new position in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 4,046,650 shares of the company's stock, valued at approximately $9,429,000. BlackRock Inc. owned 5.02% of Protalix BioTherapeutics at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of the company. Cubist Systematic Strategies LLC raised its stake in shares of Protalix BioTherapeutics by 82.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 53,380 shares of the company's stock worth $137,000 after buying an additional 24,073 shares in the last quarter. NewEdge Advisors LLC acquired a new position in Protalix BioTherapeutics during the first quarter worth $39,000. Goldman Sachs Group Inc. grew its holdings in Protalix BioTherapeutics by 482.3% during the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company's stock worth $741,000 after acquiring an additional 239,751 shares during the period. Jane Street Group LLC raised its position in Protalix BioTherapeutics by 159.0% in the first quarter. Jane Street Group LLC now owns 294,318 shares of the company's stock worth $753,000 after acquiring an additional 180,702 shares in the last quarter. Finally, Geode Capital Management LLC purchased a new position in Protalix BioTherapeutics in the second quarter worth $1,223,000. 16.53% of the stock is owned by institutional investors and hedge funds.
Protalix BioTherapeutics Stock Performance
PLX opened at $2.67 on Friday. The business's fifty day moving average is $2.40 and its two-hundred day moving average is $2.34. The company has a market cap of $215.13 million, a price-to-earnings ratio of -20.54 and a beta of 0.02. Protalix BioTherapeutics, Inc. has a one year low of $1.52 and a one year high of $3.19.
Protalix BioTherapeutics Company Profile
(
Free Report)
Protalix BioTherapeutics NYSE: PLX is a clinical‐stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost‐effective and scalable manner. Protalix's core expertise lies in engineering plant cells to generate high‐quality therapeutic proteins for rare and specialty diseases.
The company's first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.
Recommended Stories
Want to see what other hedge funds are holding PLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protalix BioTherapeutics, Inc. (NYSE:PLX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Protalix BioTherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protalix BioTherapeutics wasn't on the list.
While Protalix BioTherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
